A Naturalistic Trial of the Norwegian Sickness Absence Clinic. The NSAC Efficacy Study
Launched by NORDLANDSSYKEHUSET HF · Mar 25, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The NSAC Efficacy Study is a research trial designed to evaluate the effectiveness of the Norwegian Sickness Absence Clinic (NSAC), a health service that helps people dealing with issues like musculoskeletal disorders, anxiety, depression, and work-related stress. The goal of the NSAC is to help patients return to work faster and prevent long-term disability. In this study, 2,500 patients will be recruited and randomly assigned to one of three groups: one group will receive quick treatment within four weeks, another will have treatment after 10-14 weeks, and the third will receive a standard examination after several weeks. The researchers want to find out if the NSAC service leads to better health outcomes and quicker returns to work compared to usual care.
To participate in the trial, individuals need to be referred to the NSAC by their general practitioner and must be deemed eligible for treatment by the clinic's admission team. However, those who are considered too healthy or too sick, or do not have a relevant diagnosis, will not qualify. Participants can expect to receive care tailored to their specific needs and will be part of an important study that aims to improve how health services support people in returning to work.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \* The patient must be considered eligible for treatment at the NSAC by the admission team at the NSAC.
- Exclusion Criteria:
- • Patients considered too healthy for treatment at the NSAC, i.e. not within target group
- • Patients considered too sick for treatment at the NSAC, i.e. not within target group
- • Patients that do not have a diagnosis that is relevant for treatment at the NSAC, i.e. not within target group
- • Patients otherwise considered not within target group for the measure
- • Patients which were included in the NSAC Nudge trial (clinicaltrials identifier: NCT05006976)
- • Patients which are secondary referred from other departments/clinics within the hospital
About Nordlandssykehuset Hf
Nordlandssykehuset HF is a leading healthcare institution located in Norway, dedicated to providing high-quality medical services and advancing clinical research. As a regional hospital trust, it plays a pivotal role in delivering specialized care while fostering innovative research initiatives aimed at improving patient outcomes. With a commitment to collaboration and excellence, Nordlandssykehuset HF actively participates in clinical trials across various medical disciplines, contributing to the development of new treatments and therapies that enhance healthcare delivery in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bodø, Nordland, Norway
Sandnessjøen, Nordland, Norway
Kirkenes, Troms Og Finnmark, Norway
Tromsø, Troms Og Finnmark, Norway
Alta, Troms Og Finnmark, Norway
Patients applied
Trial Officials
Arnstein Mykletun, PhD
Principal Investigator
UiT The Arctic University of Norway
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials